Potential inhibitors designed against NDM-1 type metallo-β-lactamases: An attempt to enhance efficacies of antibiotics against multi-drug-resistant bacteria

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Khan, Asad U ^a   Ali, Abid ^a   Danishuddin, D ^a   Srivastava, Gaurava ^b   Sharma, Ashok ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE NDM-1;

BACTERIUM; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; HEMOLYSIS; HYDROGEN BOND; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; MULTIDRUG RESISTANCE; PRECLINICAL STUDY; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; BACTERIA; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMOLYSIS; HYDROGEN BONDING; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85027967368     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-09588-1     Document Type: Article

References (41)

1. Knowles, J. R. Penicillin Resistance: The Chemistry of β-Lactamase Inhibition. Acc. Chem. Res. 18, 97-104 (1985).
2. Ambler, R. P. The Structure of b-Lactamases. Philos. Trans. R. Soc. London. B, Biol. Sci. 289, 321-331 (1980).
3. González, M. M. et al. Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 Carbapenemase. ACS Infect Dis. Nov 13, 1(11), 544-54 (2015).
4. Kumarasamy, K. K. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597-602 (2010).
5. Bush, K. & Jacoby, G. A Updated functional classification of beta-lactamases. Antimicrob. Agents Chemother. 54, 969-76 (2010).
6. Walsh, M. J. et al. Identification of Selective Inhibitors ofPhosphofructokinase as Lead Compounds Against Trypanosomiasis. National Center for Biotechnology Information (US); Oct 18 [updated 2013 Feb 25] (2010).
7. Faheem, M., Rehman, M. T., Danishuddin, M. and Khan, A. U. Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-beta-lactam-beta-lactamase inhibitor. [Erratum appears in PLoS One. 8(12) (2013).
8. Skagseth, S. et al. Metallo-β-lactamase inhibitors by bioisosteric replacement: Preparation, activity and binding. Eur J Med Chem. 135, 159-173 (2017).
9. Guo, Y. et al. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. Protein Cell. 2, 384-394 (2011).
10. Zhang, H. & Hao, Q. Crystal structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. FASEB J. 25, 2574-2582 (2011).
11. Kim, Y. et al. Structure of apo- and monometalated forms of NDM-1-A highly potent carbapenem-hydrolyzing Metallo-β-lactamase. PLoS One. 6, 1-12 (2011).
12. Concha, N. O., Rasmussen, B. A., Bush, K. & Herzberg, O. Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure. 4, 823-36 (1996).
13. F. Sohi et al. structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme. Biochemistry 37(36), 12404-11 (1998).
14. Carfi, A., Duee, E., Galleni, M., Frere, J. M. & Dideberg, O. 1.85 A resolution structure of the zinc (II) beta-lactamase from Bacillus cereus. Acta Crystallogr. D. Biol. Crystallogr. 54, 313-323 (1998).
15. Khan, A., Faheem, M., Danishuddin, M. & Khan, A. U. Evaluation of inhibitory action of novel non b-lactam inhibitor against klebsiella pneumoniae carbapenemase (KPC-2). PLoS One., doi: 10.1371/journal.pone.0108246 (2014).
16. Strynadka, N. C. et al. Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 A resolution. Nature. 359, 700-705 (1992).
17. Rehman, M. T., Shamsi, H. & Khan, A. U. Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches. Mol. Pharm., doi: 10.1021/mp500116c (2014).
18. Eftink, M. R. & Ghiron, C. A. Fluorescence quenching studies with proteins. Anal. Biochem. 114, 199-227 (1981).
19. Shahabadi, N., Khorshidi, A. & Moghadam, N. H. Study on the interaction of the epilepsy drug, zonisamide with human serum albumin (HSA) by spectroscopic and molecular docking techniques. Spectrochim. Acta - Part A Mol. Biomol. Spectrosc. 114, 627-632 (2013).
20. Chen, Z. et al. Understanding the fate of an anesthetic, nalorphine upon interaction with human serum albumin: a photophysical and mass-spectroscopy approach. RSC Adv. 4, 25410-25419 (2014).
21. Ishtikhar, M. et al. Biophysical and molecular docking insight into interaction mechanism and thermal stability of human serum albumin isoforms with a semi-synthetic water-soluble camptothecin analog irinotecan hydrochloride. J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2015.1082504 (2015).
22. Keswani, N., Choudhary, S. & Kishore, N. Interaction of weakly bound antibiotics neomycin and lincomycin with bovine and human serum albumin: biophysical approach. J Biochem 148, 71-84 (2010).
23. Maîtrepierre, E., Sigoillot, M., Le Pessot, L. & Briand, L. Recombinant expression, in vitro refolding, and biophysical characterization of the N-terminal domain of T1R3 taste receptor. Protein Expr Purif. 83(1), 75-83 (2012).
24. Tronrud, D. E. Conjugate-direction minimization: an improved method for the refinement of macromolecules. Acta Crystallogr. Sect. A. 48, 912-916 (1992).
25. Brooks, B. R. et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 30, 1545-1614 (2009).
26. Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W. & Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins Struct. Funct. Genet. 52, 609-623 (2003).
27. Morris, G. & Huey, R. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 30(16), 2785-2791 (2009).
28. Wang, H., Kelkar, S., Wu, W., Chen, M. & Quinn, J. P. Clinical isolates of Enterobacteriaceae producing extended-spectrum β-lactamases: Prevalence of CTX-M-3 at a hospital in China. Antimicrob. Agents Chemother. 47, 790-793 (2003).
29. Wallace, A. C., Laskowski, R. A. & Thornton, J. M. Ligplot -a Program To Generate Schematic Diagrams of Protein Ligand Interactions. Protein Eng. 8, 127-134 (1995).
30. Hess, B., Kutzner, C., Van Der Spoel, D. & Lindahl, E. GRGMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435-447 (2008).
31. Spoel, V. D. et al. H. J. C. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701-1718 (2005).
32. Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins Struct. Funct. Bioinforma. 78, 1950-1958 (2010).
33. Sousa da Silva, A. W. & Vranken, W. F. VIP:ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res. Notes. 5, 367 (2012).
34. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926 (1983).
35. Turner, P. J. Extended-spectrum beta-lactamases. Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am., 41(Suppl 4), S273-275 (2005).
36. Cowan, R., Grosdidier, G. Visualization Tools for Monitoring and Evaluation of Distributed Computing Systems. In Proc. of the International Conference on Computing in High Energy and Nuclear Physics, Padova, Italy; Others (2000).
37. Kumari, R., Kumar, R., Lynn, A. G mmpbsa A GROMACS Tool for High-Throughput MM-PBSA Calculations. Journal of chemical information and modeling. Jun 19, 54(7), 1951-62(2014).
38. Kumari R, Lynn AM. Application of MM/PBSA in the prediction of relative binding free energy: Re-scoring of docking hit-list. Journal of Natural Science, Biology and Medicine. Dec 1, 2(3), 92 (2011).
39. Khan, A. U. & Nordmann, P. Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed. Scand. J. Infect. Dis. 44, 531-5 (2012).
40. Cheng, Y. Prusoff WH.Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 22(23), 3099-108 (1973).
41. Galleni, M. et al. Use of the chromosomal class A β-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory β-lactam compounds. Antimicrob. Agents Chemother. 38, 1608-1614 (1994).